Literature DB >> 30260417

Association between HIV-1 subtype and drug resistance in Nigerian infants.

Beth Chaplin1, Alani Sulaimon Akanmu2, Seth C Inzaule3, Jay Osi Samuels4, Prosper Okonkwo4, Oluwafunke Ilesanmi5, Isaac F A Adewole6, Chukwuemeka Asadu7, Hadiza Khamofu8, Rex Mpazanje5, Nicaise Ndembi9, Solomon Odafe10, Kim C E Sigaloff3, Evelyn Nkadi Ngige7, Emmanuel Okechukwu Abatta7, Gbenga Akinbiyi7, Patrick Dakum9, Tobias F Rinke de Wit3, Phyllis Kanki1.   

Abstract

Background: Many lines of evidence point to HIV-1 subtype-specific differences in the development of drug resistance mutations. While variation between subtype C and others has been extensively explored, there has been less emphasis on subtypes common to West Africa. We examined a previously described national survey of pretreatment drug resistance in HIV-1-infected Nigerian children aged <18 months, to explore the association between subtypes and patterns of resistance.
Methods: Five hundred and forty-nine dried blood spots, from 15 early infant diagnostic facilities in Nigeria, were amplified and HIV-1 polymerase was sequenced. Four hundred and twenty-four were analysed for surveillance drug resistance mutations (SDRMs). Associations between subtype and SDRMs were evaluated by Fisher's exact test and logistic regression analysis, controlling for geographical region and exposure.
Results: Using the sub-subtypes of HIV-1 G defined by Delatorre et al. (PLoS One 2014. 9: e98908) the most common subtypes were CRF02_AG (174, 41.0%), GWA-I (128, 30.2%), GWA-II (24, 5.7%), GCA (11, 2.6%), A (21, 5.0%) and CRF06_cpx (18, 4.2%). One hundred and ninety infants (44.8%) had ≥1 NNRTI mutation, 92 infants (21.7%) had ≥1 NRTI mutation and 6 infants (1.4%) had ≥1 PI mutation. By logistic regression, 67N was more common in GWA-II/GCA than CRF02_AG (OR 12.0, P = 0.006), as was 70R (OR 23.1, P = 0.007), 184I/V (OR 2.92, P = 0.020), the presence of ≥1 thymidine analogue mutation (TAM) (OR 3.87, P = 0.014), ≥1 type 2 TAM (OR 7.61, P = 0.001) and ≥1 NRTI mutation (OR 3.26, P = 0.005). Conclusions: This dataset reveals differences among SDRMs by subtype; in particular, between the GWA-II and GCA subclades, compared with CRF02_AG and GWA-I.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30260417     DOI: 10.1093/jac/dky380

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

Authors:  Kate El Bouzidi; Steven A Kemp; Rawlings P Datir; Fati Murtala-Ibrahim; Ahmad Aliyu; Vivian Kwaghe; Dan Frampton; Sunando Roy; Judith Breuer; Caroline A Sabin; Obinna Ogbanufe; Man E Charurat; David Bonsall; Tanya Golubchik; Christophe Fraser; Patrick Dakum; Nicaise Ndembi; Ravindra K Gupta
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

2.  Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria.

Authors:  R Datir; K El Bouzidi; P Dakum; N Ndembi; R K Gupta
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

3.  Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.

Authors:  George A Yendewa; Foday Sahr; Sulaiman Lakoh; Marta Ruiz; Lucia Patiño; Andrés Tabernilla; Gibrilla F Deen; Momodu Sesay; Robert A Salata; Eva Poveda
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

4.  Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.

Authors:  George A Yendewa; Sulaiman Lakoh; Sahr A Yendewa; Khadijah Bangura; Andrés Tabernilla; Lucia Patiño; Darlinda F Jiba; Alren O Vandy; Samuel P Massaquoi; Nuno S Osório; Gibrilla F Deen; Foday Sahr; Robert A Salata; Eva Poveda
Journal:  Genes (Basel)       Date:  2021-08-26       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.